An Overview of Hereditary Breast and Ovarian Cancer Syndrome

Journal of Midwifery and Women's Health

Volumn 57, Issue 6, 2012, Pages 577-584

  Smith, Edith Caroline ^a  

^a NONE   (United States)

Author keywords

BRCA; Breast cancer; Cancer risk; HBOC; Hereditary cancer syndrome; Ovarian cancer

Indexed keywords

AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; ESTROGEN; EXEMESTANE; ORAL CONTRACEPTIVE AGENT; PROSTATE SPECIFIC ANTIGEN; RALOXIFENE; TAMOXIFEN;

BRCA2 GENE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST SELF EXAMINATION; CANCER PREVENTION; CANCER RISK; CATARACT; CELL PROLIFERATION; CLINICAL FEATURE; DIGITAL RECTAL EXAMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DISCRIMINATION; GENETIC SCREENING; HEALTH CARE UTILIZATION; HEALTH EDUCATION; HEALTH INSURANCE; HEALTH SURVEY; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HETEROZYGOTE; HORMONE SUBSTITUTION; HUMAN; LAW; LOW DRUG DOSE; MAMMOGRAPHY; MELANOMA; MENOPAUSAL SYNDROME; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PELVIC EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REPRODUCTION; REVIEW; RISK REDUCING BILATERAL SALPHINGOOOPHORECTOMY; RISK REDUCTION; SALPINGOOOPHORECTOMY; SKIN IRRITATION; THROMBOEMBOLISM; TUMOR SUPPRESSOR GENE; UTERUS CANCER; VAGINA DISCHARGE; VOMITING; WOMEN'S HEALTH;

EID: 84870715864     PISSN: 15269523     EISSN: 15422011     Source Type: Journal    
DOI: 10.1111/j.1542-2011.2012.00199.x     Document Type: Review

References (66)

1. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975.
2. Heredity and cancer. American Cancer Society Web site. http://www.cancer.org/Cancer/CancerCauses/GeneticsandCancer/heredity-and-cancer. Reviewed and Revised December 27, 2011. Accessed January 21, 2012.
3. Palma MD, Domchek S, Stopfer J, et al. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high risk breast cancer families. Cancer Res. 2008;68(17):7006-7014.
4. Breast cancer statistics. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/cancer/breast/statistics/Updated November 23, 2010. Accessed January 21, 2012.
5. Probability of breast cancer in American women. National Cancer Institute and the National Institutes of Health Web site. http://www.cancer.gov/cancertopics/factsheet/detection/probability-breast-cancer. Reviewed September 17, 2010. Accessed January 21, 2012.
6. Lifetime risk of developing or dying from cancer. American Cancer Society Web site. http://www.cancer.org/Cancer/CancerBasics/lifetime-probability-of-developing-or-dyingfromcancer. Updated December 23, 2011. Accessed January 21, 2012.
7. Ovarian cancer overview: Survival rates for ovarian cancer. American Cancer Society Web site. http://www.cancer.org/Cancer/OvarianCancer/OverviewGuide/ovarian-cancer-overview-survival-rates. Updated December 21, 2011. Accessed January 21, 2012.
8. Rebbeck TR, Kauff ND, Domcheck SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80-87.
9. Mourits MJ, de Bock GH. Managing hereditary ovarian cancer. Maturitas. 2009;64(3):172-176.
10. Meyer LA, Anderson ME, Lacour RA, et al. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol. 2010;115(5):945-952.
11. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. NEJM. 1997;336(20):1401-1408.
12. Genetics of breast and ovarian cancer. National Cancer Institute and the National Institutes of Health Web site. http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional/page2. Updated January 18, 2012. Accessed January 21, 2012.
13. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1, 342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011;121(2):352-357.
14. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250:1684-1689.
15. Hall JM, Griedman L, Guenther C, et al. Closing in on the breast cancer gene on chromosome 17q. Am J Hum Genet. 1992;50:1235-1242.
16. Hofmann W, Schlag PM. BRCA1 and BRCA2-Breast cancer susceptibility genes. JCRCO. 2000;126:487-496.
17. Chail H. Tumor suppressor (TS) genes and the two-hit hypothesis. Nature Ed. 2008. http://www.nature.com/scitable/topicpage/tumor-suppressor-ts-genes-and-the-two-887. Accessed January 21, 2012.
18. Understanding cancer series: Cancer genomics-Two-hit hypothesis. National Cancer Institute and the National Institutes of Health Web site. http://www.cancer.gov/cancertopics/understandingcancer/cancergenomics/page53. Reviewed September 1, 2006. Accessed January 21, 2012.
19. My family health portrait. National Human Genome Research Institute. National Institutes of Health. https://familyhistory.hhs.gov/fhh-web/home.action. Accessed January 10, 2012.
20. Weitzel JN, Lagos VI, Cullinane CA, et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA. 2007;297(23):2587-2595.
21. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77:2318-2324.
22. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62:676-689.
23. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10, 000 individuals. J Clin Oncol. 2002;20:1480-1490.
24. BRCA1 and BRCA2 hereditary breast and ovarian cancer syndrome. Gene Rev. http://www.ncbi.nlm.nih.gov/sites/GeneTests/. Accessed August 15, 2011.
25. NCCN Clinical Practice Guidelines in Oncology v.1.2012. Genetic/familial high-risk assessment: breast and ovarian. http://nccn.org. Accessed September 6, 2012.
26. Myriad Genetic Laboratories. http://www.myriadpro.com/guidelines. Accessed August 2011.
27. ACOG practice bulletin. Clinical management guidelines for obstetrian-gynecologists: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2009;113(4):957-963.
28. U.S. preventative services task force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Recommendation statement. Ann Intern Med. 2005;143:355-361.
29. Metcalfe K, Gershman S, Lynch HT, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011;104(9):1384-1392.
30. Metcalfe KA, Lynch HT, Ghadirian P, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005;96(1):222-226.
31. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. JNCI. 2007;99(23):1811-1814.
32. The Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers. JNCI. 1999;15:1310-1316.
33. Thompson D, Easton DF, Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. JNCI. 2002;94(18):1358-1365.
34. Surveillance epidemiology and end results. SEER stat fact sheet: Prostate. National Cancer Institute Web site. http://seer.cancer.gov. Updated November 2011. Accessed January 21, 2012.
35. Van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet. 2005;42(9):711-719.
36. Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K. American society of clinical oncology policy statement update: Genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28(5):893-901.
37. ACOG committee opinion No 478: Family history as a risk assessment tool. Obstet Gynecol. 2011;117(3):747-750.
38. Teller P, Kramer RK. Management of asymptomatic BRCA mutation carriers. Appl Clin Genetics. 2010;3:121-131. http://www.dovepress.com/getfilephp?fileID=8206.
39. Saslow DS, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75-89.
40. Robson M, Offit K. Management of an inherited predisposition to breast cancer. NEJM. 2007;357(2):154-162.
41. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 and BRCA2 mutations. NEJM. 2002;346(21):1616-1622.
42. Society of gynecologic oncologists clinical practice committee statement of prophylactic salpingo oophorectomy. Gynecol Oncol. 2005;98(2):179-181.
43. ACOG 2008 Practice Bulletin: Elective and risk reducing salpingo-oophoorectomy. Obstet Gynecol. 2008;111(1):231-241.
44. Reynolds C, Davidson JA, Lindor NM, et al. Prophylactic and therapeutic mastectomy in BRCA mutation carriers: Can the nipple be preserved? Ann Surg Oncol. 2011;18(11):3102-3109.
45. Collaborative Group on Epidemiological Studies of Ovarian Cancer; Beral V, Doll R, Hermon C, Petro R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87, 303 controls. Lancet. 2008;371(9609):303-314.
46. Iodice S, Barile M, Rotmensz N, et al. Oral contraceptives and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer. 2010;46:2275-2284.
47. Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. JNCI. 2002;94:1773-1779.
48. Milne RL, Knight JA, John EM, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev. 2005;14(2):350-356.
49. Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study: A report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. JCO. 2007;112(S3):700-709.
50. Figueiredo JC, Haile RW, Bernstein L, et al. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and non-carriers: the WECARE Study. Breast Cancer Res Treat. 2010;120(1):175-183.
51. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res. 2011 3(6):696-706.
52. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. JNCI. 2007;99(4):272-282.
53. Vogel VG, Bevers T. Handbook of Breast Cancer Risk Assessment: Evidence-Based Guidelines for Evaluation, Prevention, Counseling, and Treatment. Sadbury, MA: Jones and Bartlett; 2003.
54. King M-C, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. JAMA. 2001;286:2251-2256.
55. National cancer institute fact sheet: Tamoxifen. National Cancer Institute and the National Institutes of Health Web site. http://www.cancer.gov/cancertopics/factsheet/Therapy/tamoxifen. Reviewed March 17, 2008. Accessed January 21, 2012.
56. Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. NEJM. 2011;364(25):2381-2391. Epub 2011 Jun 4.
57. Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol. 2005;23(31):7804-7810.
58. Brem S, Kumar N. Management of treatment-related symptoms in patients with breast cancer: current strategies and future directions. Clin J Oncol Nurs. 201;15(1):63-71.
59. Hudson KL, Holohan MK, Collins FS. Keeping pace with the times-The Genetic Information Nondiscrimination Act of 2008. NEJM. 2008;358(25):2661-2663.
60. Steck MB, Eggert JA. The need to be aware and beware of the Genetic Information Nondiscrimination Act. Clin J Onc Nurs. 2011;15(3):E34-E41.
61. Greely HT. Banning genetic discrimination. NEJM. 2005;353(9):865-867.
62. Bright Pink. http://www.bebrightpink.org. Accessed August 15, 2011.
63. Facing our risk of cancer empowered. http://www.facingourrisk.org. Accessed August 15, 2011.
64. National Ovarian Cancer Coalition. http://www.ovarian.org. Accessed August 15, 2011.
65. National Society of Genetic Counselors. http://www.nsgc.org. Accessed August 15, 2011.
66. National Human Genome Research Institute. http://www.genome.gov. Accessed August 15, 2011.